StockNews.AI
AUTL
StockNews.AI
14 hrs

Autolus Therapeutics to Present Clinical Data Update at the American College of Rheumatology (ACR) Convergence 2025

1. Autolus will present CARLYSLE study findings at ACR Convergence 2025. 2. Obe-cel demonstrated a manageable safety profile with no dose-limiting toxicities. 3. All patients showed clinical benefit and reduced SLEDAI-2K scores. 4. The data indicates significant renal responses in three patients.

4m saved
Insight
Article

FAQ

Why Bullish?

The positive study results suggest potential for future product approval and market expansion. Historical events show that similar announcements often boost stock prices.

How important is it?

The successful findings from CARLYSLE could lead to wider adoption of therapies, positively affecting sales.

Why Long Term?

The impact will likely manifest as results progress and commercial viability is proven over time.

Related Companies

AUCATZYL
LONDON and GAITHERSBURG, Md., Sept. 16, 2025 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), an early commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies, announces the online publication of an abstract submitted to the American College of Rheumatology (ACR) Convergence 2025, to be held October 24-29, 2025, in Chicago. Autolus will have a poster presentation, which will include updated follow up from the CARLYSLE study in patients with severe refractory systemic lupus erythematosus (srSLE). Abstract: 2458Title: Obecabtagene autoleucel (obe-cel), a CD19-targeting autologous chimeric antigen receptor T-cell therapy (CAR T) with a fast off-rate binding domain, in patients with severe, refractory systemic lupus erythematosus (srSLE): preliminary results from the Phase I CARLYSLE studySession date and time: Tuesday, October 28, 2025; 10:30am - 12:30pm Central TimePresenting Author: Maria Leandro, MD Summary: Initial findings from the ongoing CARLYSLE study of obe-cel in srSLE show a manageable safety profile, with no dose limiting toxicities (DLTs), immune effector cell-associated neurotoxicity syndrome (ICANS) or Grade ≥2 cytokine release syndrome (CRS). SLEDAI-2K score reduction and clinical benefit were observed in all patients. In addition, three patients who had a complete renal response. Updated data will be presented at the conference. About Autolus Therapeutics plc Autolus Therapeutics plc (Nasdaq: AUTL) is an early commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation T cell therapies and candidates for the treatment of cancer and autoimmune disease. Using a broad suite of proprietary and modular T cell programming technologies, Autolus is engineering precisely targeted and controlled T cell therapies that are designed to better recognize target cells, break down their defense mechanisms and eliminate these cells. Autolus has a marketed therapy, AUCATZYL®, and a pipeline of product candidates in development for the treatment of hematological malignancies, solid tumors and autoimmune diseases. For more information, please visit www.autolus.com.  Contact:   Amanda Cray +1 617-967-0207 a.cray@autolus.com 

Related News